Analysis shows Johnson & Johnson's latest 13F filing reveals holdings in 15 biotech stocks, with Protagonist Therapeutics being the largest investment, whose stock price has surged 65% year-to-date.
According to Yahoo Finance analysis, Johnson & Johnson's latest 13F filing (as of June 30, 2026) disclosed its holdings of 15 stocks in the biotechnology and medical technology sectors. The analysis indicates that Johnson & Johnson's largest investment is in Protagonist Therapeutics, amounting to approximately $300 million. Protagonist Therapeutics had one product launched in the US in March 2026, and the FDA approval decision for another product, rusfertide, is expected in August 2026. As of August 28, 2026, Protagonist Therapeutics' stock price has risen by 65% year-to-date.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
CoreWeave's default probability exceeds 60%, but NVIDIA CEO Jensen Huang states its financing costs are decreasing and NVIDIA is not required to backstop it.
-
2
UKMTO Warns of "Severe" Threat to Shipping in Strait of Hormuz, Attacks "Highly Likely"
-
3
CoreWeave Credit Default Swaps Hit Distressed Levels Amid Investor Concerns Over AI Debt
-
4
AWS, Anthropic, OpenAI and Google are racing to deploy specialized AI engineers to help companies realize returns on their AI investments
-
5
MSCI adopts new index exclusion rules; Strategy and Metaplanet may face removal, SharpLink placed on review list.
-
6
Fed's Hammack: Financial conditions do not appear restrictive right now
-
7
US embassy warns of potential attacks on Saudi airports, restricts staff travel and urges citizens to take extreme caution
-
8
MSCI Launches Consultation to Reclassify Indonesia Equity Indexes from Emerging to Standalone Market Status
-
9
Porsche CEO Michael Leiters discusses new Mission S supercar, China market, and future of EVs
-
10
Balaji Srinivasan's Network School acquires Farcaster; users must sign 'social smart contract' or get read-only access
Markets Today
Recommended Reading


